<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639729</url>
  </required_header>
  <id_info>
    <org_study_id>IAP102</org_study_id>
    <nct_id>NCT01639729</nct_id>
  </id_info>
  <brief_title>Effect of Delivery Route on PK of Sufentanil NanoTab</brief_title>
  <official_title>Effect of Delivery Route on the Pharmacokinetics of Sufentanil NanoTab® in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcelRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcelRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine whether the amount of drug absorbed is different if the tablet is placed under the
      tongue, placed between the cheek and gum, or swallowed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0 - Inf)</measure>
    <time_frame>24 hours</time_frame>
    <description>total amount of sufentanil absorbed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 hours</time_frame>
    <description>time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CST 1/2</measure>
    <time_frame>24 hours</time_frame>
    <description>time for maximum plasma concentration to decrease by 50%</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Sequence 1 - Treatment A, B, C, D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 - Treatment A, B, D, C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3 - Treatment A, C, B, D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4 - Treatment A, C, D, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5 - Treatment A, D, B, C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6 - Treatment A, D, C, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A: Sufentanil IV</intervention_name>
    <description>Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)</description>
    <arm_group_label>Sequence 1 - Treatment A, B, C, D</arm_group_label>
    <arm_group_label>Sequence 2 - Treatment A, B, D, C</arm_group_label>
    <arm_group_label>Sequence 3 - Treatment A, C, B, D</arm_group_label>
    <arm_group_label>Sequence 4 - Treatment A, C, D, B</arm_group_label>
    <arm_group_label>Sequence 5 - Treatment A, D, B, C</arm_group_label>
    <arm_group_label>Sequence 6 - Treatment A, D, C, B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B: Sufentanil NanoTab Sublingual</intervention_name>
    <description>Single Sufentanil NanoTab 15 mcg given sublingually (SL)</description>
    <arm_group_label>Sequence 1 - Treatment A, B, C, D</arm_group_label>
    <arm_group_label>Sequence 2 - Treatment A, B, D, C</arm_group_label>
    <arm_group_label>Sequence 3 - Treatment A, C, B, D</arm_group_label>
    <arm_group_label>Sequence 4 - Treatment A, C, D, B</arm_group_label>
    <arm_group_label>Sequence 5 - Treatment A, D, B, C</arm_group_label>
    <arm_group_label>Sequence 6 - Treatment A, D, C, B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: Sufentanil NanoTab Buccal</intervention_name>
    <description>Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)</description>
    <arm_group_label>Sequence 1 - Treatment A, B, C, D</arm_group_label>
    <arm_group_label>Sequence 2 - Treatment A, B, D, C</arm_group_label>
    <arm_group_label>Sequence 3 - Treatment A, C, B, D</arm_group_label>
    <arm_group_label>Sequence 4 - Treatment A, C, D, B</arm_group_label>
    <arm_group_label>Sequence 5 - Treatment A, D, B, C</arm_group_label>
    <arm_group_label>Sequence 6 - Treatment A, D, C, B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D: Sufentanil NanoTab Oral</intervention_name>
    <description>Single Sufentanil NanoTab 15 mcg swallowed (PO)</description>
    <arm_group_label>Sequence 1 - Treatment A, B, C, D</arm_group_label>
    <arm_group_label>Sequence 2 - Treatment A, B, D, C</arm_group_label>
    <arm_group_label>Sequence 3 - Treatment A, C, B, D</arm_group_label>
    <arm_group_label>Sequence 4 - Treatment A, C, D, B</arm_group_label>
    <arm_group_label>Sequence 5 - Treatment A, D, B, C</arm_group_label>
    <arm_group_label>Sequence 6 - Treatment A, D, C, B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index 18 - 30

        Exclusion Criteria:

          -  pregnant females

          -  smokers

          -  pulmonary disease

          -  sleep apnea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Palmer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AcelRx Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Willsie SK, Evashenk MA, Hamel LG, Hwang SS, Chiang YK, Palmer PP. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. Clin Ther. 2015 Jan 1;37(1):145-55. doi: 10.1016/j.clinthera.2014.11.001. Epub 2014 Dec 24.</citation>
    <PMID>25544247</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <results_first_submitted>November 25, 2013</results_first_submitted>
  <results_first_submitted_qc>April 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2014</results_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>area under curve</keyword>
  <keyword>time to maximum concentration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: Treatment A, B, C, D</title>
          <description>Treatment A: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Treatment B: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Treatment D: Single Sufentanil NanoTab 15 mcg swallowed (PO)
A 48-hour washout period will separate each treatment period. The washout begins with the start of dosing.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: A, B, D, C</title>
          <description>Treatment A: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Treatment B: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Treatment D: Single Sufentanil NanoTab 15 mcg swallowed (PO)
A 48-hour washout period will separate each treatment period. The washout begins with the start of dosing.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3: Treatment A, C, B, D</title>
          <description>Treatment A: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Treatment B: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Treatment D: Single Sufentanil NanoTab 15 mcg swallowed (PO)
A 48-hour washout period will separate each treatment period. The washout begins with the start of dosing.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4: Treatment A, C, D, B</title>
          <description>Treatment A: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Treatment B: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Treatment D: Single Sufentanil NanoTab 15 mcg swallowed (PO)
A 48-hour washout period will separate each treatment period. The washout begins with the start of dosing.</description>
        </group>
        <group group_id="P5">
          <title>Sequence Five: Treatments A, D, B, C</title>
          <description>Treatment A: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Treatment B: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Treatment D: Single Sufentanil NanoTab 15 mcg swallowed (PO)
A 48-hour washout period will separate each treatment period. The washout begins with the start of dosing.</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6: Treatments A, D, C, B</title>
          <description>Treatment A: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Treatment B: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Treatment D: Single Sufentanil NanoTab 15 mcg swallowed (PO)
A 48-hour washout period will separate each treatment period. The washout begins with the start of dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomly assigned to one of 6 sequences</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment A, Followed by Treatment B, C and D in Random Order</title>
          <description>Treatment A: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV) Treatment B: Single Sufentanil NanoTab 15 mcg given sublingually (SL) Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU) Treatment D: Single Sufentanil NanoTab 15 mcg swallowed (PO) Sequence 1: A, B, C, D Sequence 2: A, B, D, C Sequence 3: A, C, B, D Sequence 4: A, C, D, B Sequence 5: A, D, B, C Sequence 6: A, D, C, B A 48-hour washout period separated each treatment period. The washout began with the start of dosing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (0 - Inf)</title>
        <description>total amount of sufentanil absorbed</description>
        <time_frame>24 hours</time_frame>
        <population>A The number of subjects (n) in Treatment D was less than the total 22 subjects for the following PK parameters: AUC 0-inf (n=18).</population>
        <group_list>
          <group group_id="O1">
            <title>Sufentanil IV</title>
            <description>Sufentanil : 15 mcg IV
PK sampling 0 (predose), 1, 4, 7, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O2">
            <title>Sufentanil NanoTab Buccal</title>
            <description>Sufentanil : 15 mcg buccal
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O3">
            <title>Sufentanil NanoTab Sublingual</title>
            <description>Sufentanil : 15 mcg sublingual
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O4">
            <title>Sufentanil NanoTab Oral</title>
            <description>Sufentanil : 15 mcg oral
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0 - Inf)</title>
          <description>total amount of sufentanil absorbed</description>
          <population>A The number of subjects (n) in Treatment D was less than the total 22 subjects for the following PK parameters: AUC 0-inf (n=18).</population>
          <units>h.pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.8" spread="61.1"/>
                    <measurement group_id="O2" value="212.5" spread="57.0"/>
                    <measurement group_id="O3" value="163.4" spread="52.5"/>
                    <measurement group_id="O4" value="24.9" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>maximum plasma concentration</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sufentanil IV</title>
            <description>Sufentanil : 15 mcg IV
PK sampling 0 (predose), 1, 4, 7, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O2">
            <title>Sufentanil NanoTab Buccal</title>
            <description>Sufentanil : 15 mcg buccal
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O3">
            <title>Sufentanil NanoTab Sublingual</title>
            <description>Sufentanil : 15 mcg sublingual
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O4">
            <title>Sufentanil NanoTab Oral</title>
            <description>Sufentanil : 15 mcg oral
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum plasma concentration</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.1" spread="312.0"/>
                    <measurement group_id="O2" value="58.9" spread="25.7"/>
                    <measurement group_id="O3" value="40.6" spread="14.8"/>
                    <measurement group_id="O4" value="4.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>time to maximum plasma concentration</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sufentanil IV</title>
            <description>Sufentanil : 15 mcg IV
PK sampling 0 (predose), 1, 4, 7, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O2">
            <title>Sufentanil NanoTab Buccal</title>
            <description>Sufentanil : 15 mcg buccal
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O3">
            <title>Sufentanil NanoTab Sublingual</title>
            <description>Sufentanil : 15 mcg sublingual
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O4">
            <title>Sufentanil NanoTab Oral</title>
            <description>Sufentanil : 15 mcg oral
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>time to maximum plasma concentration</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.02" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.67" upper_limit="2.07"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.33" upper_limit="1.50"/>
                    <measurement group_id="O4" value="1.11" lower_limit="0.67" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CST 1/2</title>
        <description>time for maximum plasma concentration to decrease by 50%</description>
        <time_frame>24 hours</time_frame>
        <population>The number of subjects (n) in Treatment D was less than the total 22 subjects for the following PK parameters: CST½ (n=16).</population>
        <group_list>
          <group group_id="O1">
            <title>Sufentanil IV</title>
            <description>Sufentanil : 15 mcg IV
PK sampling 0 (predose), 1, 4, 7, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O2">
            <title>Sufentanil NanoTab Buccal</title>
            <description>Sufentanil : 15 mcg buccal
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O3">
            <title>Sufentanil NanoTab Sublingual</title>
            <description>Sufentanil : 15 mcg sublingual
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
          <group group_id="O4">
            <title>Sufentanil NanoTab Oral</title>
            <description>Sufentanil : 15 mcg oral
PK sampling 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480, 600, 720, and 840 minutes and 24 hours after dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>CST 1/2</title>
          <description>time for maximum plasma concentration to decrease by 50%</description>
          <population>The number of subjects (n) in Treatment D was less than the total 22 subjects for the following PK parameters: CST½ (n=16).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.05" upper_limit="0.68"/>
                    <measurement group_id="O2" value="2.28" lower_limit="0.13" upper_limit="4.67"/>
                    <measurement group_id="O3" value="2.50" lower_limit="1.50" upper_limit="4.83"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.83" upper_limit="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sufentanil IV</title>
          <description>Sufentanil : 15 mcg IV</description>
        </group>
        <group group_id="E2">
          <title>Sufentanil NanoTab Buccal</title>
          <description>Sufentanil : 15 mcg buccal</description>
        </group>
        <group group_id="E3">
          <title>Sufentanil NanoTab Sublingual</title>
          <description>Sufentanil : 15 mcg sublingaul</description>
        </group>
        <group group_id="E4">
          <title>Sufentanil NanoTab Oral</title>
          <description>Sufentanil : 15 mcg oral</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>photophobia</sub_title>
                <description>all subjects received naltrexone 50 mg BID</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>flat effect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>requires prior approval</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Palmer</name_or_title>
      <organization>AcelRx</organization>
      <phone>650-216-3500</phone>
      <email>ppalmer@acelrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

